Morgan Crucible Co PLC
13 February 2008
The Morgan Crucible Company plc announces that on 13 February 2008 it purchased
for cancellation from JPMorgan Cazenove Limited 220,000 ordinary shares at an
average price of 184.88 pence per share.
Accordingly, upon settlement of the above transaction, The Morgan Crucible
Company plc's capital will consist of 270,829,074 25p ordinary shares with
voting rights, and 437,281 cumulative preference shares (125,327 5.5% cumulative
first preference shares of £1.00 each and 311,954 5% cumulative second
preference shares of £1.00 each), with no voting rights, save in specified
limited circumstances.
Therefore, the total number of shares with voting rights in The Morgan Crucible
Company plc will be 270,829,074.
The above figure 270,829,074 may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, The Morgan Crucible Company
plc under the FSA's Disclosure and Transparency Rules.
Enquiries
The Morgan Crucible Company plc 01753 837 000
Paul Boulton
END
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.